Key Points
- COO Jeremy Chadwick sold 25,758 shares on March 11 at an average of $83.30 for about $2.15M, reducing his stake by 27.46% to 68,052 shares valued at roughly $5.67M.
- Kymera posted weak quarterly results, missing EPS expectations with a ($0.97) loss versus ($0.77) expected and reporting $2.87M in revenue versus $14.8M expected, a 60.8% year-over-year decline.
- Analysts remain generally positive: MarketBeat shows a consensus rating of "Moderate Buy" with an average target of $119.50, and several firms have recently raised price targets (e.g., JPMorgan to $125).
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) COO Jeremy Chadwick sold 25,758 shares of the company's stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $83.30, for a total transaction of $2,145,641.40. Following the completion of the sale, the chief operating officer directly owned 68,052 shares of the company's stock, valued at $5,668,731.60. The trade was a 27.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Kymera Therapeutics Stock Down 3.6%
NASDAQ KYMR opened at $81.52 on Thursday. The firm has a market cap of $6.66 billion, a P/E ratio of -22.15 and a beta of 2.20. Kymera Therapeutics, Inc. has a 52-week low of $19.44 and a 52-week high of $103.00. The business's 50-day moving average price is $79.09 and its 200 day moving average price is $67.82.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The company had revenue of $2.87 million for the quarter, compared to analysts' expectations of $14.80 million. During the same period in the prior year, the company earned ($0.88) earnings per share. The firm's revenue was down 60.8% on a year-over-year basis. As a group, analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the business. US Bancorp DE lifted its position in shares of Kymera Therapeutics by 9.8% in the third quarter. US Bancorp DE now owns 1,865 shares of the company's stock valued at $106,000 after acquiring an additional 166 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Kymera Therapeutics by 9.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company's stock worth $156,000 after purchasing an additional 248 shares in the last quarter. Larson Financial Group LLC raised its stake in Kymera Therapeutics by 36.9% in the 4th quarter. Larson Financial Group LLC now owns 1,064 shares of the company's stock valued at $83,000 after purchasing an additional 287 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in Kymera Therapeutics by 3.3% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 12,655 shares of the company's stock valued at $985,000 after purchasing an additional 410 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its holdings in Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock valued at $42,000 after purchasing an additional 424 shares in the last quarter.
Analysts Set New Price Targets
KYMR has been the subject of several recent research reports. Wells Fargo & Company increased their price target on Kymera Therapeutics from $69.00 to $116.00 and gave the stock an "overweight" rating in a report on Tuesday, December 9th. Royal Bank Of Canada restated an "outperform" rating and set a $108.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, February 26th. JPMorgan Chase & Co. lifted their target price on shares of Kymera Therapeutics from $70.00 to $125.00 and gave the company an "overweight" rating in a report on Wednesday, December 10th. Bank of America boosted their price target on shares of Kymera Therapeutics from $71.00 to $112.00 and gave the stock a "buy" rating in a research note on Tuesday, December 9th. Finally, Mizuho increased their price target on shares of Kymera Therapeutics from $81.00 to $120.00 and gave the stock an "outperform" rating in a report on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $119.50.
Read Our Latest Stock Report on KYMR
About Kymera Therapeutics
(
Get Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
